Meridian is conducting research studies of investigational vaccines intended to protect against SARS-CoV-2 (the coronavirus that causes COVID-19). Studies will begin in Nebraska, Georgia, and South Dakota.
OMAHA, Neb. (PRWEB) April 30, 2020
Meridian Clinical Research, a leading investigative research network, is seeking participants for COVID-19 vaccine clinical trials in the following areas: Nebraska (Norfolk and Omaha), Georgia (Savannah), and South Dakota (Dakota Dunes).
The studies will help determine the safety and efficacy of investigational vaccines intended to protect against SARS-CoV-2 (the coronavirus that causes COVID-19). To be eligible, participants must:
- Be adults, age 18 or older
- Not have a history of SARS-CoV-2 infection
- Not be pregnant or breastfeeding
Eligible participants will receive compensation for participating and do not need health insurance to join. People interested in joining a study can sign up for more information at mcrmed.com/covid or call a Meridian call center: (402) 934-7563 (NE, SD) • (912) 623-2240 (GA).
Meridian has enrolled more than 42,000 patients into clinical trials since 1999, and is a leading investigative site network for vaccine trials. In 2015, the company supported studies for the Ebola vaccine when the outbreak occurred, and conducted research for Zika virus and anthrax vaccines in the past year.
Meridian will remain fully-staffed and operational through the COVID-19 pandemic, and is working to meet or exceed all federal and state safety guidelines at its sites nationwide.
Sponsors and CROs interested in leveraging Meridian’s network for vaccine trials should email Andrew Kimball, VP of Business Development, at firstname.lastname@example.org.
To learn more about Meridian, visit mcrmed.com.
About Meridian Clinical Research
Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new pharmaceutical drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty site network that conducts Phase I-IV clinical trials nationwide, and specializes in vaccine and infectious disease research. For more information, visit mcrmed.com.